Brenton Karl Ahrens is Director at Iterum Therapeutics plc (ITRM). They have made 7 open-market trades across 3 companies since 2011, most recently 2022-09-20.
CIK 0001322927
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
2 open-market purchases totalling $11.6M since 2012, against 5 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ITRM | SELL | 2022-09-16 | 2022-09-20 | $1.82 | $68K | -8.5% | +5.6% | -43.6% |
| ITRM | SELL | 2022-09-13 | 2022-09-15 | $2.09 | $94K | -17.5% | -12.5% | -43.0% |
| ITRM | SELL | 2022-09-08 | 2022-09-12 | $2.31 | $77K | -22.7% | -25.8% | -49.3% |
| ITRM | BUY | 2018-05-30 | 2018-05-30 | $13.00 | $6.6M | -3.9% | -14.6% | -18.9% |
| DRTX | BUY | 2012-07-24 | 2012-07-26 | $9.00 | $5.0M | N/A | N/A | N/A |
| ACTV | SELL | 2012-03-02 | 2012-03-06 | $16.00 | $3.1M | N/A | N/A | N/A |
| ACTV | SELL | 2011-05-31 | 2011-06-02 | $15.00 | $20.6M | N/A | N/A | N/A |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.